Company intelligence / Profile preview
Skin2Neuron
Sydney, New South Wales, Australias2n.bio ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Successfully reversed dementia-like syndrome in dogs with a natural form of Alzheimer's disease. Animal studies have shown significant improvement in memory functions, with treated dogs becoming "non-demented" within 3-6 months post-procedure. Histology data demonstrated the cells' ability to arrange themselves into functional neural networks that can supplant brain tissue degraded by disease.
- Therapeutic areas
- Neurology
- Modalities
- Cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Major global top 5 pharma partner (unnamed)
Beyond the preview
Go deeper on Skin2Neuron.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skin2Neuron.